According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
Patients with BRCA mutations often face aggressive disease and poor prognosis
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
